Description

Axetin Coated (Cefuroxime) Tablets 500 mg. №10

Ingredients:

Each tablet contains 500 mg of cefuroxime as the active ingredient.

Mechanism of Action:

Cefuroxime, a second-generation cephalosporin antibiotic, inhibits bacterial cell wall synthesis, leading to bacterial cell death.

Pharmacological Properties:

Cefuroxime exerts its effects by disrupting bacterial cell wall synthesis, causing cell lysis and death. It demonstrates broad-spectrum activity against Gram-positive and Gram-negative bacteria and exhibits good tissue penetration.

Indications for Use:

Axetin coated tablets are indicated for the treatment of respiratory tract infections, skin and soft tissue infections, and urinary tract infections caused by susceptible bacteria.

Contraindications:

Axetin tablets should not be used in individuals with a known hypersensitivity to cefuroxime or other cephalosporin antibiotics.

Side Effects:

Common side effects may include gastrointestinal disturbances, allergic reactions, and skin rashes. Serious side effects are rare but may include severe allergic reactions.

Usage Instructions:

The typical adult dosage ranges from 250 mg to 500 mg every 12 hours. Follow the dosage regimen prescribed by your healthcare provider and swallow the tablet whole with a full glass of water.

Benefits Compared to Analogues:

Axetin tablets offer comparable efficacy to other antibiotics in the treatment of bacterial infections while maintaining a favorable safety profile.

Suitable Patient Groups:

Axetin tablets are suitable for use in adults, including the elderly population. The dosage may need adjustment in patients with renal impairment.

Storage and Shelf Life:

Store Axetin coated tablets at room temperature, away from moisture and heat. Keep out of reach of children. Check the expiration date before use.

Packaging Description:

Axetin tablets are available in blister packs containing 10 tablets each.

Clinical Evidence and Proven Effectiveness:

In a study published in the Journal of Antimicrobial Chemotherapy, cefuroxime demonstrated comparable effectiveness to other antibiotics in the management of community-acquired pneumonia. The study highlighted similar clinical outcomes and safety profiles, supporting the use of cefuroxime in respiratory infections.